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Strengths and limitations of this study
 ► This report is the first to profile and compare the 
prevalence of a treatable deficit of vision that de-
velops in childhood (amblyopia) among children 
living in Ireland and Northern Ireland (NI), UK; two 
populations with similar refractive, demographic 
and genetic profiles but different public health and 
eye-care systems.
 ► An observational, population-based approach with 
random cluster sampling and comparable method-
ologies was used to obtain sufficiently large data 
sets from the two cohorts in Ireland and NI, allowing 
a direct comparison of prevalence.
 ► The randomly selected population-based recruit-
ment protocols eliminate the potential bias associ-
ated with clinical samples.
 ► The participants in the Ireland (12–13 years old) and 
NI (9–10 and 15–16 years old) cohorts, while dif-
ferent age categories, were all older than the age 
range where treatment is effective (that is treatment 
before the age of 8 years).
 ► Pinhole vision was used as a surrogate for best-cor-
rected vision.
AbStrACt
Objectives This study reports the prevalence of 
persistent amblyopia (post-traditional treatment age) 
in schoolchildren in the Republic of Ireland (henceforth 
Ireland) and Northern Ireland (NI), UK; populations with 
broadly similar refractive and genetic profiles but different 
eye-care systems.
Design This is a population-based observational study of 
amblyopia and refractive error.
Setting Recruitment and testing in primary and post-
primary schools in Ireland and NI.
Participants Two groups identified through random 
cluster sampling to represent the underlying population; 
Ireland 898 participants (12–13 years old) and NI 723 
participants (295 aged 9–10 years old, 428 aged 15–
16 years old).
Main outcome measures Monocular logMAR visual 
acuity (presenting and pinhole), refractive error 
(cycloplegic autorefraction), ocular alignment (cover test) 
and history of previous eye care. These metrics were 
used to determine prevalence and type of amblyopia and 
treatment histories.
results Children examined in NI between 2009 and 
2011 had a significantly lower amblyopia prevalence 
than children examined in Ireland between 2016 and 
2018 (two-sample test of proportions, p<0.001). Using 
a criteria of pinhole acuity 0.2logMAR (6/9.5 Snellen) 
plus an amblyogenic factor, 4 of 295 participants aged 
9–10 years old (1.3%, 95% CIs 0.4 to 3.6) and 3 of 428 
participants aged 15–16 years old (0.7%, 95%CIs 0.2 to 
2.2) were identified in NI. The corresponding numbers 
in Ireland were 40 of 898 participants aged 12–13 years 
old (4.5%, 95% CI 3.2 to 6.1). In NI strabismic amblyopia 
was the most prevalent type of persistent amblyopia, 
whereas anisometropic was predominant in Ireland. In 
Ireland, amblyopia was associated with socioeconomic 
disadvantage (OR=2.2, 95%CIs 1.4 to 3.6, p=0.002) and 
poor spectacle compliance (OR 2.5, 95% CIs 2.0 to 3.2, 
p<0.001).
Conclusions Amblyopia prevalence persisting beyond 
traditional treatment ages was significantly lower 
among NI children compared with Ireland. Uncorrected 
anisometropia, compliance with spectacle wear and 
socioeconomic disadvantage were contributing factors in 
Ireland. Children without obvious visible eye defects were 
less likely to access eye care in Ireland, resulting in missed 
opportunities for intervention where necessary.
IntrODuCtIOn
This paper reports on the first-ever amblyopia 
prevalence study in Ireland and compares 
findings with Northern Ireland (NI). Ambly-
opia, often referred to as ‘lazy eye’, is a rela-
tively common, sight-threatening, but mostly 
treatable deficit of monocular, and occasion-
ally, binocular vision.1 It results from anom-
alous visual experience during the critical 
period of visual development in the early years 
of childhood2 and may affect multiple aspects 
of visual function.2–4 For example, untreated 
amblyopia does not self-rectify,5 impacts 
reading skills6 and significantly increases the 
 o
n
 M
ay 6, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031066 on 10 August 2019. Downloaded from 
2 Harrington S, et al. BMJ Open 2019;9:e031066. doi:10.1136/bmjopen-2019-031066
Open access 
Table 1 A summary of public health service funded school-entry vision screening protocols and paediatric eye care services 
in Ireland and Northern Ireland
Age Ireland Northern Ireland (UK)
School entry 4–5 years Monocular vision assessment at 5 years 
(Snellen 3M chart or logMAR crowded 
3M chart) is conducted by the school 
nurse.
Pass: Vision of 0.2logMAR in both eyes.
Fail: Vision worse than 0.2logMAR in one 
or both eyes or failure to complete the 
test.
Failed vision screening referred to 
hospital-based ophthalmology/
community ophthalmology for follow-up. 
Children remain in this system for review 
until discharged at age 12–16 years.20
Once an eye examination is carried out 
in a hospital or community health clinic, 
children under the age of 12 years can 
apply for a voucher which will cover 
the cost of basic frames and lenses. 
Eye patches for occlusion therapy are 
not provided free of charge; this cost is 
covered by the parents.
Monocular vision assessment at 4–5 years 
(logMAR crowded 3M chart) is conducted by 
the school nurse.
Pass: Vision of 0.2logMAR in both eyes.
Fail: Vision worse than 0.2logMAR in one or 
both eyes or failure to complete the test.
Failed vision screening referred to hospital 
eye service (orthoptist, optometrist, 
ophthalmology) for follow-up. The 
recommended maximum treatment duration 
(treatment pathway) for refractive amblyopia 
is 38 weeks and for strabismic amblyopia 78 
weeks; with children discharged to the care of 
their community optometrist once treatment is 
complete.19
All children are entitled to a voucher which 
covers the price basic spectacles and lenses. 
The cost of eye patches for amblyopia 
treatment is covered by the National Health 
Service.
Post-school entry If concerned, contact the general 
practitioner or public health nurse for 
a referral to a local ophthalmology 
department.
Attend high street optometrist (free of charge 
for all children under 16 years and under 19 
years if still in education) and referred onto 
tertiary care with ophthalmology if indicated.
risk of severe visual impairment of both eyes in later life.4 7 
Amblyopia may affect an individual’s quality of life, sports 
involvement,8 9 self-esteem,10 educational attainment4 
and career choice.10 Annual lost earnings in the USA due 
to amblyopia have been estimated at $7 billion.11 Due to 
the nature of the condition, treatment in early childhood 
(before the age of 8 years),12 13 when there is potential to 
improve vision, is essential.12–14
Amblyopia has a variety of causes: strabismic (ocular 
misalignment), anisometropic (a significant difference 
in refractive error between fellow eyes), form deprivation 
(exclusion of all visual information except light due to 
physical obstructions such as corneal/lenticular opacifi-
cation or eyelid ptosis), significant uncorrected refractive 
error (high levels of astigmatism or hyperopia) or a combi-
nation of these features.1 15 Anisometropic amblyopia is 
asymptomatic in younger children, due to the clear image 
in the non-amblyopic eye, and this coupled with the lack 
of any obvious physical signs (straight eyes) can delay diag-
nosis4 16 and is associated with poorer compliance with 
treatment and spectacle wear.17 Although less common, 
high degrees of uncorrected refractive error in both eyes 
can result in bilateral (in both eyes) amblyopia.18
In Ireland and NI, publicly funded vision screening 
programmes to detect reduced vision are recommended at 
school entry. Conducting screening at this age (4–5 years) 
balances the impetus for early identification of visual defi-
cits in order to implement the most effective treatment 
with the need for children to cooperate with appropriately 
sensitive visual acuity tests.19 While school-entry vision 
screening recommendations and protocols are similar in 
both countries (table 1), there are important differences 
in terms of coverage, the postfailure pathway and the 
context in which the public health systems operate. Specif-
ically, in NI all children are offered vision screening and 
children up to the age of 16 years (and up to 19 years if still 
in education) are entitled to free eye examinations and a 
voucher towards the cost of spectacles through self-referral 
to community (high street) optometry. Prompt referral 
to the hospital eye service for secondary care treatment 
can be initiated directly, with the cost of eye patches for 
occlusion therapy covered if required. In contrast, in order 
to obtain free eye care and a voucher towards the cost of 
spectacles in Ireland, children are referred into the public 
health system, where care is offered by ophthalmologists 
either in public hospital outpatients departments or in 
community healthcare clinics. The recent Health Service 
Executive review evaluating eye care services in Ireland 
identified concerns regarding capacity in public eye care 
services and the uniformity and reach of childhood vision 
screening.20
The purpose of this study is to report and compare the 
prevalence and cause of persistent amblyopia post-tradi-
tional treatment age (8 years)5 21 in two broadly similar 
population cohorts (in Ireland and NI) with an equiva-
lent genetic profile and similar refractive error preva-
lence,22 but different healthcare systems.
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MethODS
This study was a component of the Ireland Eye Study (IES) 
and the Northern Ireland Childhood Errors of Refrac-
tion (NICER) study, both observational population-based 
studies of visual status among schoolchildren in Ireland 
and NI. Ethical approval for the IES (20150305-Siofra 
Harrington, Ref 15–03) and NICER study (REC/05/121) 
was obtained from the Technological University Dublin 
Research Ethics Committee and the Ulster University 
Research Ethics Committee, respectively, with both 
studies adhering to the Tenets of Helsinki Declaration 
of Human Studies. Sampling, recruitment protocols and 
participation rates are previously published.22 23 Data 
collection took place between 2016 and 2018 in Ireland 
and between 2009 and 2011 in NI; best-corrected visual 
acuity (BCVA) data presented in the present study are 
from phase II (3-year follow-up) of the NICER study as 
this metric was not recorded in the initial phase of the 
NICER study.
In summary, stratified random sampling was employed 
in both studies to obtain representative samples of chil-
dren in Ireland and NI schools. Schools were catego-
rised by urban/rural status (urban: Ireland 751 of 898 
participants (83.6%), NI 414 of 723 participants (57.3%); 
rural: Ireland 147 of 898 participants (16.4%), 309 of 
723 participants (42.7%)) and socioeconomic status 
(disadvantaged: Ireland 108 of 898 participants (12.1%), 
NI 337 of 723 participants (46.6%); advantaged: 790 
of 898 participants (87.9%), 386 of 723 participants 
(53.4%)). Ethnicity was assessed by the study coordi-
nator and confirmed by the parent/guardian response 
in the study questionnaire. Both study populations were 
predominately white (NICER 98%, IES 88.4% white and 
the remainder 11.6% were non-white (East Asian 3.3%, 
South Asian 1.7%, black 5.5%, Arab 1.1% combined)). 
Only data from participants at an age beyond which treat-
ment is likely to be successful (>8 years old)12–14 were used 
in the present analysis. Participants were 898 participants 
aged 12–13 years living in Ireland and 723 participants 
(295 aged 9–10 years and 428 aged 15–16 years) living in 
NI.
Procedures
Children with written informed consent and child assent 
were examined on their school premises within school 
hours. Experimental techniques and methodology 
employed in both the NICER study and the IES have been 
described in detail elsewhere.22–24 In summary, both the 
NICER study and the IES examination involved:
1. Distance monocular crowded logMAR unaided and 
presenting (with spectacles if worn) visual acuities 
were measured and scored by-letter with and without 
a pinhole.
IES—using the Good-Lite (Elgin, Illinois, USA) Sloan 
letters logMAR chart. A light metre was employed to 
ensure the test luminance did not fall below 120 cd/
m2; and the NICER study—logMAR chart on the Test 
Chart 2000, a Windows-based electronic test chart 
(http://www. thomson- software- solutions. com/ html/ 
test_ chart_ 2000. html).
2. Ocular alignment was evaluated using a cover–uncover 
test and an alternating cover test using an accommo-
dative target with and without spectacle correction (if 
worn) in the distance (3 m) and near (40 cm IES and 
33 cm NICER).
3. Cycloplegic autorefraction, at least 20 min postinstil-
lation of anaesthetic (Minims Proxymetacaine Hydro-
chloride 0.5% w/v, Bausch & Lomb, UK) and cyclople-
gic eye drops (Minims Cyclopentolate Hydrochloride 
1% w/v, Bausch & Lomb).
4. Direct dilated ophthalmoscopy examination of the an-
terior segment and the lens vitreous and fundus was 
carried out on all participants in Ireland and any ab-
normalities were noted.
5. Parents/legal guardians completed a participant and 
parental history and a children’s lifestyle questionnaire 
detailing, inter alia, history of eye surgery, history of oc-
clusion therapy and spectacle wear and whether partic-
ipants had their eyes tested with an ophthalmologist or 
optometrist within 12 months before data collection.
6. Public involvement: the IES study questionnaire was 
based on the NICER study questionnaire with input 
from epidemiology, dietetics and focus group feed-
back. The questionnaire was refined following multisite 
user testing, which involved a cognitive walkthrough 
evaluation to assess the burden associated with and the 
time to complete the questionnaire.25 Following focus 
group feedback, a storyboard which outlined the IES 
examination was designed to make the study clear to 
children; the questionnaire was shortened by remov-
ing non-essential questions and simplifying the word-
ing of the remaining questions to maximise accessibili-
ty; and a statement advising parents/guardians to skip 
any questions they felt uncomfortable answering was 
added to the document.
7. Follow-up: subsequent to the examination, all parents 
or legal guardians involved in both studies received a 
detailed report advising them of study findings and the 
necessity of any further treatment if required.
Definitions
To facilitate comparison with previous studies, amblyopia 
prevalence in this study was analysed and presented using 
two definitions:
Criteria (A) Multiethnic paediatric eye disease study 
(MEPEDS) definition: Unilateral amblyopia; ≥2 line 
interocular difference in visual acuity, measured through 
a pinhole, with BCVA of 0.2logMAR (6/9.5 Snellen, 
20/32) or poorer in the worse eye in the presence of 
a unilateral amblyogenic factor consistent with the 
affected eye. Amblyogenic factors included strabismus 
at a distance and near fixation with/without spectacle 
correction, a history of strabismus surgery, anisometropia 
(≥1.00 D difference in hyperopia, ≥3.00 D difference 
in myopia, ≥1.50 D difference in astigmatism in any 
meridian).26
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Bilateral amblyopia: BCVA poorer than 0.3logMAR 
(6/12 Snellen, 20/40) in both eyes in the presence of a 
bilateral amblyogenic factor.26
Criteria (B) Refractive error study in children (RESC) defini-
tion: Amblyopia was defined as BCVA (measured through 
a pinhole) ≥0.3logMAR (≤6/12 Snellen, 20/40) in at 
least one eye associated with one or more of the following 
potential causes: (1) esotropia, exotropia or vertical 
tropia at 4 m fixation, or esotropia or vertical tropia at 
0.5 m (strabismic amblyopia); (2) anisometropia of ≥2D 
spherical equivalent refractive error (SER) (anisome-
tropic amblyopia); or (3) hyperopia of ≥6D SER.
Unilateral amblyopia: If only one eye met the criteria.
Bilateral amblyopia: If both eyes met the criteria 
separately.27
Participants with a history of amblyopia treatment were 
not categorised as having persistent amblyopia unless 
they met criteria A or criteria B.
To examine the magnitude of amblyopic visual acuity 
deficits, based on the BCVA in the amblyopic eye, severe 
amblyopia was defined as BCVA >0.6logMAR.28
All refractive errors were measured using autorefrac-
tion under cycloplegia and defined as follows: myopia SER 
≤−0.50 dioptre sphere (DS), hyperopia SER ≥+2.00 DS 
and astigmatism ≥1.00 dioptre cylinder (DC).22
Statistical methodology
The authors collected the primary data which were 
entered into databases which were used for subsequent 
analysis. The NICER study used Intercooled Stata V.9.2 
(StataCorp, Texas, USA). The Statistical Package for 
Social Sciences (SPSS) V.24.0 was used for most analyses in 
the IES. The statistical programming language R, RStudio 
V.1.1.456 (R Foundation for Statistical Computing, 
Vienna, Austria), was used to generate random numbers 
for the sampling procedure, to provide prevalence data 
CIs and for comparing the prevalence of amblyopia, 
anisometropia, strabismus, spectacle wear and history of 
amblyopia treatment between the two populations, and 
to calculate the OR for amblyopia plus CIs. The sample 
sizes required (n=716 in both cohorts) were based on a 
predictive amblyopia prevalence of 1.9% (which included 
those previously treated for amblyopia), in predominately 
European Caucasian Australian 12 years old,29 with a 
0.95 confidence level and a 0.01 precision estimate. The 
sample size was estimated as follows using Cochran’s 
sample size formula30: n=sample size,
Z=1.96 with confidence level=0.95 (for alpha=0.05), 
d=desired precision of estimate=0.01,
P=0.019 (the estimated proportion)
 
n =
[(
1.96
)(
0.019
)(
1−0.019)](
0.01
)
 
Result: n=716.04
The two-sample test for equality of proportions with 
continuity correction was used to compare prevalence 
between populations. Logistic regression analysis was 
used to examine the relationship between amblyopia 
prevalence and associated factors; participants without 
amblyopia were the reference category. The 5% level of 
significance was used throughout; CIs were 95%.
reSultS
Table 2 displays amblyopia prevalence for the right eye, 
left eye, either eye, unilateral and bilateral for both 
study groups (Ireland 12–13 years old and NI 9–10 and 
15–16 years old) using criteria A and criteria B. All partici-
pants in NI were older than the critical treatment age and 
as there was no significant difference in amblyopia preva-
lence between the participants aged 9–10 and 15–16 years 
old in NI using either criterion; unless otherwise stated, 
amblyopia prevalence refers to amblyopia prevalence in 
either eye for participants aged 9–16 years old in NI and 
participants aged 12–13 years old in Ireland using criteria 
A. Amblyopia prevalence was 4.5% (40 of 898 partici-
pants) within the Ireland study (IES). The corresponding 
result for the NI (NICER) study participants was 1.0% (7 
of 723 participants). Participants in Ireland were signifi-
cantly more likely to be amblyopic than participants in 
NI, OR 4.8 (95%CIs 2.1 to 10.7, p<0.001). Table 2 displays 
amblyopia prevalence in 898 Ireland participants aged 
12–13 years (second column table 2), and 723 NI partici-
pants aged 9–16 years (final column table 2). Amblyopia 
prevalence is also presented for the two age cohorts in the 
NICER study: 9–10 years old (first column table 2) and 
15–16 years old (third column table 2).
The study questionnaire completion rate was between 
99.4% (history of spectacle wear and when last exam-
ined by an ophthalmologist or optometrist) and 99.7% 
(history of eye surgery or amblyopia treatment). Using the 
parental questionnaire data, 24 of 40 amblyopic partici-
pants (60%) in Ireland had not had their eyes examined 
by an eye-care practitioner during the 12 months before 
data collection.
Forty-five of 723 NI participants (6.2%) reported a 
history of amblyopia treatment, and only 1 of 723 partic-
ipants aged 9–10 years old (0.02%) remained amblyopic. 
In comparison, 68 of 898 participants (7.6%) reported 
a history of amblyopia treatment in Ireland; however, of 
these, 24 of 898 participants (2.7%) remained ambly-
opic; 10 of 898 (1.1%) of which had BCVA poorer than 
0.6logMAR in their amblyopic eye. While the incidence of 
prior amblyopia treatment did not differ between studies 
(p=0.61), successful treatment outcomes were signifi-
cantly poorer in the Ireland study (p<0.001).
In Ireland, 12 of 898 participants (1.3%) reported a 
history of strabismus surgery; 8 of 898 (0.9%) of which 
were not categorised as having persistent amblyopia; 
a history of strabismus surgery was not associated with 
persistent amblyopia in Ireland (p=0.25). All participants 
in Ireland with a history of eye surgery reported having 
attended an ophthalmologist or optometrist for review 
within 12 months of participation in the present study.
Table 3 presents the prevalence of anisometropia 
and strabismus in Ireland and NI studies, including 
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Table 3 Prevalence of anisometropia, strabismus and mixed mechanism anisometropia in Ireland (12–13 years) and NI (9–10 
and 15–16 years)
Anisometropia 
strabismus status
9–10 years (295)
Prevalence (%, CIs)
NI P value*
12–13 years (898)
Prevalence (%, CIs)
IRELAND P value†
15–16 years (428) 
Prevalence (%, CIs)
NI
Anisometropia 26 (8.8) (6.0 to 12.8) 0.27 102 (11.2) (9.4 to 13.7) 0.59 43 (10.2) (7.4 to 13.4)
Strabismus 17 (5.8) (3.5 to 9.2) 0.35 38 (4.2) (3.1 to 5.8) 0.68 21 (4.9) (3.1 to 7.5)
Anisometropia+strabismus 4 (1.4) (0.5 to 3.9) 0.99 13 (1.4) (0.8 to 2.5) 0.61 4 (0.1) (0.2 to 3.8)
Strabismus only 13 (4.4) (2.6 to 7.4) 0.24 25 (2.8) (1.8 to 4.1) 0.34 17 (4.0) (2.2 to 7.2)
Anisometropia only 22 (7.5) (4.8 to 11.6) 0.25 89 (9.9) (8.1 to 12.1) 0.72 39 (9.1) (5.4 to 14.9)
*Comparison of anisometropia, strabismus and mixed aetiology prevalence between Ireland (12–13 years old) and NI (9–10 years old).
†Comparison of anisometropia, strabismus and mixed aetiology prevalence between the 15–16 years old in the NI study and 12–13 
years old in Ireland.
D, dioptre; N, number;NI, Northern Ireland.
Table 4 Prevalence of refractive error, anisometropia, strabismus, and mixed aetiology in 898 participants aged 12–13 years 
old in Ireland and 723 participants aged 9–16 years old in NI
Ireland (12–13 years) 898
N (%) (95%CIs)
NI (9–16 years) 723
N (%) (95%CIs) P value
Hyperopia (≥2.00 D) 80 (8.9) (7.2 to 11.0) 94 (13.0) (10.7 to 15.7) 0.01
Myopia (≤−0.50 D) 179 (19.9) (17.4 to 22.7) 110 (15.2) (12.7 to 18.1) 0.02
Astigmatism (≥1.00 DC) 143 (15.9) (13.5 to 18.4) 128 (17.7) (15.0 to 20.7) 0.38
Anisometropia (≥1.00 IOD) 102 (11.2) (9.4 to 13.7) 69 (9.5) (7.6 to 12.0) 0.27
Strabismus 38 (4.2) (3.1 to 5.8) 38 (5.3) (4.0 to 7.2) 0.40
Mixed aetiology 13 (1.4) (0.8 to 2.5) 8 (1.1) (0.5 to 2.3) 0.70
D, dioptre; DC, dioptre cylinder; IOD, interocular difference; N, number; NI, Northern Ireland.
participants with and without amblyopia. Table 4 pres-
ents the prevalence of hyperopia, myopia, astigmatism, 
anisometropia, strabismus and mixed aetiology (coexisting 
anisometropia plus strabismus) in the 898 participants 
aged 12–13 years old in Ireland and the 723 participants 
aged 9–16 years old in NI. There was no significant differ-
ence in the prevalence of either anisometropia or stra-
bismus or mixed aetiology (coexisting anisometropia 
plus strabismus) between the participants in Ireland and 
NI (all p>0.05, see table 3 and table 4). There was no 
significant difference in the prevalence of astigmatism 
between the Ireland and NI participants. Figure 1 displays 
the prevalence of anisometropia, strabismus and mixed 
mechanism anisometropia plus strabismus in the 898 
participants aged 12–13 years old in Ireland and the 723 
participants aged 9–16 years old in NI.
Causes of amblyopia
For those participants classified as having amblyopia in 
the Ireland and NI studies, the reasons for amblyopia are 
illustrated in table 5.
In Ireland, anisometropia was the most frequent cause 
of persistent amblyopia, followed by a combination of 
anisometropia and strabismus (mixed aetiology), stra-
bismus only. In the NI study, strabismus was the primary 
cause of persistent amblyopia; only one participant had 
mixed aetiology, and one participant had anisometropia.
Level of amblyopic visual acuity Nine participants in 
Ireland had severe amblyopia (BCVA poorer than 
0.6logMAR); all were anisometropic, three also had stra-
bismus and all reported a history of amblyopia treatment. 
One NI participant aged 9–10 years old had severe ambly-
opia; this participant had strabismus, hyperopia and was a 
bilateral hypermetropic astigmat with a history of ambly-
opia treatment.
Bilateral amblyopia In Ireland, five participants had 
bilateral amblyopia (criteria A): one had strabismus, one 
had mixed aetiology and the remainder refractive error 
(hypermetropic astigmatism). In the NI study, two partic-
ipants (0.3%) had bilateral amblyopia (aged 9–10 years 
old); both were orthotropic with uncorrected refrac-
tive error (hypermetropic astigmatism). There were no 
NICER participants aged 15–16 years old with bilateral 
amblyopia.
Spectacle wear The prevalence of spectacle wear was 
significantly higher (p<0.001) in NI (61 of 295 partici-
pants (20.7%) aged 9–10 years, and 146 of 428 partici-
pants (34.1%) aged 15–16 years) compared with Ireland 
(123 of 898 participants aged 12–13 years (13.8%)). In  on
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Figure 1 The prevalence of anisometropia, strabismus and 
mixed aetiology (coexisting strabismus and anisometropia) 
in 898 participants aged 12–13 years old in Ireland and 723 
participants aged 9–16 years old in Northern Ireland.
Table 5 Causes of amblyopia in either eye for children in Ireland (12–13 years) and NI (9–10 years old, 15–16 and 9–16 years 
old combined)
Ocular outcomes
NI (295)
9–10 years n (%)
Ireland (898)
12–13 years n (%)
NI (428)
15–16 years n (%)
NI (723)
9–16 years n (%)
Criteria A (MEPEDS)
  Anisometropia 1 (25) 21 (52.5) 0 (0.0) 1 (14.2)
  Strabismus 2 (50.0) 5 (12.5) 1 (33.0) 3 (43.0)
  Mixed mechanism 1 (25.0) 6 (15.0) 0 (0.00) 1 (14.2)
  Refractive error 0.0 8 (22.5) 2 (66.0) 2 (28.6)
Criteria B (RESC)
  Anisometropia 1 (25) 19 (57.6) 0 (0.0) 1 (16.7)
  Strabismus 2 (50.0) 3 (9.1) 1 (50.0) 3 (50.0)
  Mixed mechanism 1 (25.0) 5 (15.2) 0 (0.00) 1 (16.7)
  Refractive error 0.0 6 (21.2) 1 (50.0) 1 (16.7)
NI, Northern Ireland; n, number.
Ireland, a further 96 of 898 participants (10.7%) did not 
have their spectacles in school.
In Ireland, 13 of the 40 amblyopic participants 
(32.5%) never had spectacles, of which 1 had strabismus, 
and the remainder had uncorrected refractive error 
(anisometropia and hyperopic astigmatism). Ten of the 
40 amblyopic participants (25.0%) were wearing specta-
cles, 6 of which had strabismus and 4 had anisometropia. 
Seventeen of the 40 amblyopic participants (42.5%) did 
not have their spectacles in school, 4 of which had stra-
bismus and the remainder had anisometropia.
Other factors associated with amblyopia
Socioeconomic disadvantage was significantly associated 
with amblyopia in Ireland (OR=2.2, 95%CIs 1.4 to 3.6, 
p=0.002). Amblyopia prevalence was 9.3% (10 of 108 
participants) in socioeconomically disadvantaged partic-
ipants compared with 3.8% (30 of 790 participants) in 
socioeconomically advantaged participants. There was a 
larger number of socioeconomically disadvantaged partic-
ipants in NI (337 of 723 participants 46.6%, compared 
with Ireland 108 of 898 participants 12%); however, socio-
economic disadvantage was not associated with ambly-
opia in the NI study. It should be noted that the definition 
of disadvantaged in NI referred to a disadvantaged area 
where a school was located,24 whereas the definition of 
disadvantaged in Ireland referred to a threshold number 
of pupils in a school coming from a disadvantaged area.22
Amblyopia prevalence did not vary with ethnicity in 
Ireland (criteria A: white 4.7% (37 of 794 participants), 
non-white 2.9% (3 of 104 participants), p=0.41, criteria B: 
white 3.8% (30 of 794 participants), non-white 2.9% (3 of 
104 participants), p=0.65). All NI participants were white.
Amblyopia was not associated with urban or rural living 
in Ireland or NI.
DISCuSSIOn
This report is the first to profile and compare the preva-
lence of amblyopia in children living in Ireland and NI; 
two populations with broadly similar refractive, demo-
graphic and genetic profiles but different public health 
and eye-care systems. Common methodology, including 
cycloplegic refraction, and definitions were applied in 
both cohorts, allowing a direct comparison of prevalence. 
Both cohorts sample size was sufficient to accurately deter-
mine amblyopia prevalence. Furthermore, the randomly 
selected population-based recruitment protocols elimi-
nated the potential bias associated with clinical samples. 
The greater than 99% questionnaire completion rate was 
most likely due to public involvement in the design stage 
of the study. These novel data demonstrate that children 
living in Ireland are more likely to retain amblyopia into 
teenage years compared with children living in NI. Study 
findings ought to provide the prevalence estimates neces-
sary to inform public healthcare policy on the resources 
required to address amblyopia. Data collection took place 
in 2009–2010 in the NICER study phase II and between 
2016 and 2018 in Ireland. The impact of any material 
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socioeconomical and educational changes during the 
intervening years should be considered; however, while 
there has been an increasing use of technology in educa-
tion, household living standards have not changed mate-
rially over the last decade with less than 0.6% growth per 
annum in real wages (allowing for inflation) in Ireland 
( www. cso. ie)31 and a 7% loss in real wages in the UK 
between 2006 and 2015 according to the International 
Labour Organisation.32
The prevalence of two key amblyogenic factors, stra-
bismus and anisometropia, did not differ significantly 
between the two cohorts. However, the visual outcome 
of children with these conditions was markedly different 
in the two countries. Strabismic amblyopia was the most 
common type of amblyopia which persisted beyond the 
traditional treatment period in the NI group, whereas 
anisometropic amblyopia was the most common type of 
persistent amblyopia in Ireland. The relatively low preva-
lence of anisometropic amblyopia and the relatively higher 
level of spectacle ownership and compliance among the 
NI children compared with their counterparts in Ireland 
demonstrate that potential or manifest anisometropic 
amblyopes were successfully identified and treated with 
spectacles. Participation in NICER phase I may have led 
to a heightened awareness among the parents of that 
cohort group of the importance of spectacle compliance 
and compliance with amblyopia treatment. However, 
NICER phase I reported spectacle compliance of 76% 
in 6–7 years old and 77% in 12–13 years old, which was 
higher than the IES where spectacle compliance was 65% 
in 12–13 years old.33 Therefore, spectacle compliance was 
higher in NI than Ireland in advance of NICER phase 
I. Furthermore, the older age cohort in NICER phase I 
of 12–13 years old were older than the critical treatment 
period.12 13Also, there was no significant difference in 
amblyopia prevalence between the 9–10 years old and 
15–16 years old in the NICER phase II. Previous studies 
demonstrated that anisometropic amblyopia is typically 
amenable to spectacle correction and that early imple-
mentation of refractive adaptation protocols is successful 
in resolving anisometropic amblyopia in the majority of 
children.18 34 35
Early childhood vision screening protocols are designed 
to identify reduced vision and are one of the primary 
means by which anisometropia without associated stra-
bismus is detected, and hence potential anisometropic 
amblyopes identified and offered treatment.19 Parents are 
less likely to seek eye care when children have no obvious 
signs or symptoms of visual impairment compared with 
parents of children who have manifest strabismus.16 
However, early recognition of children with reduced 
vision at screening is only the first step in identifying and 
successfully treating amblyopia. Successful treatment of 
amblyopia is age-sensitive; so timely referral for diagnosis 
and treatment is key.12 The disparity between the primary 
aetiology of residual amblyopia in the Ireland and NI 
cohorts, with anisometropia being the primary aetiology 
associated with residual amblyopia in children in Ireland, 
may be indicative of inadequate vision screening coverage 
(Ireland 80%, NI 95%),36 and lack of timely access to 
eye care and spectacle correction and compliance with 
amblyopia treatment in Ireland.37 For example, ambly-
opia was associated with socioeconomic disadvantage in 
Ireland where the onus is on parents to fund the cost of 
eyepatches for amblyopia therapy; in contrast, this cost is 
funded by the state in NI.
Similar numbers of children in Ireland and NI had 
been previously treated for amblyopia. Approximately 
one-third (35.3%, 24 of 68 participants) in Ireland with a 
history of amblyopia treatment presented with amblyopia, 
indicating poor compliance with treatment or that treat-
ment is taking place too late.38 Furthermore, 10 of those 
(17%, 10 of 68) with a history of treatment presented 
with vision poorer than 0.6logMAR (6/24 Snellen) in 
one eye. In NI, only one child with a history of ambly-
opia treatment presented with reduced acuities. Delays of 
over 2 years between screening and treatment have been 
acknowledged in Ireland.20 While Clarke et al found a 
1-year delay in commencing treatment does not adversely 
affect the visual outcomes of young children with small 
interocular acuity differences, the authors concluded 
early treatment is associated with better outcomes.39 Also, 
following the introduction of free preschool education 
in 2010, children in Ireland may be older commencing 
primary school than children in NI.40 Thus conducting 
vision screening in preschool, as practised in Denmark,41 
ought to be considered.
Bilateral amblyopia was uncommon. The prevalence did 
not differ significantly between the two cohorts. Although 
the numbers were small, bilateral amblyopia has more 
severe consequences as vision is significantly impaired in 
both eyes (five children in Ireland and two in NI were 
below the legal minimum driving vision standard). All but 
one of the participants categorised as bilaterally ambly-
opic were orthotropic; hence, amblyopia may have been 
prevented with compliant spectacle wear alone.42
Even though anisometropia and strabismus are tradi-
tionally reported as the primary causes of amblyopia inter-
nationally,26 27uncorrected astigmatism is also a significant 
issue for participants both in NI and Ireland. Astigmatism 
prevalence in NI (6–7 years 24.0%, 12–13 years 20.0%) 
and Ireland (6–7 years 19.2%, 12–13 years 15.9%) is 
high,22 43 and similar to other studies involving genetically 
isolated populations, it is significantly associated with 
persistent amblyopia in both cohorts.44 However, the low 
prevalence of persistent amblyopia found in NI partici-
pants in the present study demonstrates that early inter-
vention and treatment can successfully reduce the risk of 
developing amblyopia in susceptible children.
In addition to quantifying a significant public health 
concern in Ireland, these data are a valuable addition to 
the limited literature on amblyopia prevalence, partic-
ularly the prevalence of residual amblyopia after treat-
ment. Amblyopia prevalence rates in studies around the 
world vary depending on the definitions used and popu-
lation studied. The RESC reported an overall amblyopia 
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prevalence of 0.74%, which ranged from 0.28% in African 
participants aged 5–15 years old to 1.43% in Hispanic 
participants aged 5–15 years old.27 In studies which 
involved Asian populations, amblyopia prevalence 
was 0.95% in the Chinese (predominately Han) aged 
5–15 years old in the RESC27 which was similar to that 
found in Chinese (Hani) aged 7–8 years old (0.97%), 
although slightly higher than that reported in Chinese 
(Hani) aged 13–14 years old (0.65%).45 In contrast, a 
higher amblyopia prevalence was reported in UK partic-
ipants aged 7 year olds (3.6%)46 and Polish participants 
aged 3–12 years old (3.1%).47 Indeed comparison of the 
present study’s findings to previous studies in other coun-
tries is not straightforward primarily because of the use 
of different definitions for amblyopia48 and variations 
in study methodology. For instance, similar to the Avon 
Longitudinal Study of Parents and Children (ALSPAC),49 
pinhole acuity was used as a surrogate for BCVA, which 
facilitates comparison of study findings between Ireland 
and NI. A recent study demonstrated good agreement 
between pinhole acuity and BCVA and recommended 
it as a test for visual impairment not correctable with 
spectacles. This surrogacy ought to be considered 
when comparing results with studies where subjectively 
measured BCVA is reported.50 Furthermore, clarification 
is needed on whether reported amblyopia prevalence 
findings include figures for those previously treated for 
amblyopia.29 The present paper reports data relating to 
persistent amblyopia in older children after the critical 
period during which treatment is usually applied.
Amblyopia prevalence found in NI (9–16 years 1.0%) 
was significantly lower than in Ireland (12–13 years 4.5%) 
and also than other studies such as the ALSPAC (7 years 
3.4%) study46 and the MEPEDS study in the USA (5–7 
years Hispanic 3.1%, Asian 1.1%).51 Amblyopia preva-
lence in NI was comparable to the Sydney Childhood Eye 
Study (12 years 0.4%), which rose to 1.9% when partic-
ipants previously treated for amblyopia were included 
and Denmark (11–12 years 1.5%) where preschool vision 
screening has been in operation for 30 years.41 Further-
more, the Sydney-based study reported a reduction in 
amblyopia prevalence compared with the Blue Mountains 
study (also Australian), where 3.9% of the adult partici-
pants were diagnosed with amblyopia.29 52 Similarly, ambly-
opia prevalence decreased from 2.9% in Danish adults53 
to 1.5% following the initiation of the Danish preschool 
screening programme.41 Likewise, the present study 
reports a lower level of amblyopia in NI than that found 
10 years previously in a retrospective study involving clin-
ical data, where a 2.02% amblyopia prevalence was found 
in 8 years old in NI.54 In contrast, amblyopia prevalence 
in Ireland (4.5%) was similar to that found in British mili-
tary recruits (4.4%) prior to the advent of comprehensive 
vision screening and amblyopia treatment in the UK.55 
In addition, the Baltimore screening project found an 
amblyopia prevalence of 3.9% among socioeconomically 
disadvantaged inner-city children in Baltimore,56 with 
persistent amblyopia associated with poor compliance.57
Future research which investigates the reasons for 
poor spectacle compliance and poor treatment outcomes 
in Ireland when compared with NI is important. For 
example, longitudinal studies and audits of the present 
systems in Ireland and NI to examine the number of 
children referred for treatment and the proportion who 
attend for follow-up examination, the age at which ambly-
opia treatment and spectacles wear was initiated and the 
duration of and compliance with treatment are indicated 
in order to bring amblyopia prevalence in Ireland in 
line with NI. Electronic health records would facilitate 
analysis and audit of the present healthcare systems and 
allow trends to be monitored over time.58 Public eye 
health education directed at parents, teachers and the 
wider community is essential to promote spectacle and or 
amblyopia treatment compliance in vulnerable children.
COnCluSIOn
This study is the first to report amblyopia prevalence 
in Ireland and the UK using robust methodologies and 
sampling to obtain a representative sample of children. 
The data reveal that school vision screening followed 
by prompt follow-up treatment results in successful 
outcomes in susceptible children, as evidenced by the 
UK participants in NI. The present study also reveals 
inequality in children’s visual outcomes in two countries 
with an equivalent genetic profile and similar prevalence 
of amblyogenic factors but different public health systems 
and access to eye care. Children living in Ireland, where 
school-entry vision screening coverage is less comprehen-
sive, free eye care less accessible and long waiting times 
exist, have a higher prevalence of amblyopia, which was 
associated with socioeconomic disadvantage. While most 
children in Ireland with visible eye defects were treated, 
uncorrected refractive error and poor spectacle compli-
ance were critical issues. Future studies examining the 
for poor spectacle compliance in Ireland compared with 
NI are recommended. Consideration should be given to 
implementing changes, including public eye-care aware-
ness programmes aimed at bringing the visual outcomes 
of children in Ireland in line with children in NI.
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